Abstract:Abstract Type I interferons (IFN-Is) are paradoxically associated with both the success and failure of immune checkpoint blockade (ICB), with increased inflammation in the tumor associated with better response. To understand how IFN-Is modulate the immune response to ICB, we developed a mass cytometry approach to quantify pro- and anti-inflammatory features of IFN-I responsiveness at the single cell level. Using high dimensional analysis we show that the inflammatory responses that are beneficial in the peripheral blood are the opposite of what is considered beneficial in the tumor, thus identifying a functional disconnect between the peripheral and tumor immune compartments. We demonstrate that an initial resistance to IFN-I by CD4 T effector (Teff) cells in the peripheral blood is strongly associated to long-term benefit of anti-PD1 therapy in patients with melanoma, head and neck and lung cancers. By contrast, a strong IFN-I response correlates with progression and low survival probability. Upregulation of PDL1 by IFN-I did not relate to response, however patients with myeloid cells that initially reacted to IFN-I with higher IDO1 induction survived longer after anti-PD1. Single-cell RNA-sequencing stratified based on response to IFN-I identified transcriptional programs associated with therapy response, providing mechanistic insight into the peripheral cell states prior to therapy conducive to anti-PD1 success. Thus, contrary to a benefit of an initially inflamed tumor environment, an initially restrained CD4 Teff inflammatory response to IFN-I averts therapy failure and enables tumor control. This IFN-I response potential is a promising new biomarker for prediction of which patients will benefit most from anti-PD1 therapy. Supported by Canadian Institutes of Health Research (CIHR) Foundation Grant FDN148386, the Canadian Cancer Society (CCSRI) Innovation Award No. 706230, the National Institutes of Health (NIH) grant AI085043, The Terry Fox New Frontiers Grant the Scotiabank Research Chair to D.G.B, the Princess Margaret Hold’em for Life Cancer Research Fellowship (G. M. B).

Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy

Peripheral CD4 T cell resistance to type I interferon defines outcome of PD1 blockade therapy in human cancer

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Targeting type I interferon tumor entry by anti-PD-L1 creates feedforward antitumor responses to overcome innate and adaptive resistance

Suppression of Type I Ifn Signaling in Tumors Mediates Resistance to Anti-Pd-1 Treatment That Can Be Overcome by Radiotherapy

Interferon-γ driven differentiation of monocytes into PD-L1 and MHC II macrophages and the frequency of Tim-3 tumor-reactive CD8 T cells within the tumor microenvironment predict a positive response to anti-PD-1-based therapy in tumor-bearing mice

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy

Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy Response.

Data from Immune-Related Gene Expression Profiling after PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Peripheral Blood Lymphocytes Differentiation Patterns in Responses / Outcomes to Immune Checkpoint Blockade Therapies in Non-Small Cell Lung Cancer: a Retrospective Study

Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade

Type I Interferon Activates PD-1 Expression Through Activation of the STAT1-IRF2 Pathway in Myeloid Cells

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy

Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer

Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma